MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
notes payable -...
$327,000
Proceeds from issuance of
common...
$150,000
Proceeds from issuance of
convertible notes...
$56,000
Proceeds from
subscription...
$50,000
Proceeds from issuance of
series b convertible...
$25,000
Net cash provided by
financing activities
$527,000
Canceled cashflow
$81,000
Net decrease in cash
-$73,391
Canceled cashflow
$527,000
Accrued
expenses-Nonrelated Party
$326,196
Accrued
interest-Related Party
$199,323
Accrued
interest-Nonrelated Party
$194,920
Stock-based
compensation-Options
$100,600
Prepaid expenses
-$80,375
Interest expense -
amortization of debt...
$79,951
Accounts payable
$40,494
Non-cash interest
expense - warrants
$32,992
Accrued compensation
$24,670
Warrant modification
expense
$17,200
Accrued
expenses-Related Party
$14,500
Interest expense -
amortization of debt...
$6,686
Stock-based
compensation-Warrant
$3,875
Repayment of convertible
notes payable
$75,000
Payment of debt issuance
costs
$6,000
Net cash used in
operating activities
-$600,391
Canceled cashflow
$1,121,782
Net loss
-$1,481,851
Prepaid expenses -
research and development
$209,427
Change in fair value of
derivative and warrant...
$30,610
Other current assets
$285
Back
Back
Cash Flow
Cell Source, Inc. (CLCS)
Cell Source, Inc. (CLCS)
source: myfinsight.com